Background: Access to psychedelic drugs is liberalizing, yet responses are highly unpredictable. It is therefore imperative that we improve our ability to predict the nature of the acute psychedelic experience to improve safety and optimize potential therapeutic outcomes. This study sought to validate the 'Imperial Psychedelic Predictor Scale' (IPPS), a short, widely applicable, prospective measure intended to be predictive of salient dimensions of the psychedelic experience.

Methods: Using four independent datasets in which the IPPS was completed prospectively - two online surveys of 'naturalistic' use ( = 741, = 836) and two controlled administration datasets ( = 30, = 28) - we conducted factor analysis, regression, and correlation analyses to assess the construct, predictive, and convergent validity of the IPPS.

Results: Our approach produced a 9-item scale with good internal consistency (Cronbach's = 0.8) containing three factors: set, rapport, and intention. The IPPS was significantly predictive of 'mystical', 'challenging', and 'emotional breakthrough' experiences. In a controlled administration dataset ( = 28), multiple regression found set and rapport explaining 40% of variance in mystical experience, and simple regression found set explained 16% of variance in challenging experience. In another ( = 30), rapport was related to emotional breakthrough explaining 9% of variance.

Conclusions: Together, these data suggest that the IPPS is predictive of relevant acute features of the psychedelic experience in a broad range of contexts. We hope that this brief 9-item scale will be widely adopted for improved knowledge of psychedelic preparedness in controlled settings and beyond.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11496213PMC
http://dx.doi.org/10.1017/S0033291724002204DOI Listing

Publication Analysis

Top Keywords

psychedelic predictor
8
psychedelic experience
8
controlled administration
8
9-item scale
8
set rapport
8
ipps predictive
8
regression set
8
psychedelic
7
validation imperial
4
imperial psychedelic
4

Similar Publications

Psilocybin: From Psychiatric Pariah to Perceived Panacea.

Am J Psychiatry

January 2025

Department of Psychiatry and Behavioral Sciences (Fonzo, Barksdale, Nemeroff) and Center for Psychedelic Research and Therapy (Fonzo, Nemeroff), University of Texas at Austin Dell Medical School, Austin; Institute for Early Life Adversity Research, University of Texas at Austin, Austin (Fonzo, Nemeroff); Department of Behavioral Health, Walter Reed National Military Medical Center, Bethesda, MD (Wolfgang); Department of Psychiatry, Uniformed Services University of the Health Sciences, Bethesda, MD (Wolfgang); Department of Psychiatry, Yale University School of Medicine, New Haven, CT (Wolfgang, Krystal); Butler Hospital, Department of Psychiatry and Human Behavior, Warren Alpert Medical School, Brown University, Providence, RI (Carpenter); Department of Psychiatry and Behavioral Neurobiology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham (Kraguljac); Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA, Los Angeles (Grzenda); Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (McDonald); Department of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis (Widge); Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA (Rodriguez); Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (Rodriguez).

Objective: The authors critically examine the evidence base for psilocybin administered with psychological support/therapy (PST) in the treatment of psychiatric disorders and offer practical recommendations to guide future research endeavors.

Methods: PubMed was searched for English-language articles from January 1998 to November 2023, using the search term "psilocybin." A total of 1,449 articles were identified and screened through titles and abstracts.

View Article and Find Full Text PDF

Effect of agreement between clinician-rated and patient-reported PTSD symptoms on intensive outpatient treatment outcomes.

Psychiatry Res

January 2025

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 12 Executive Park Drive NE, 3rd Floor, Atlanta, GA, 30329, United States. Electronic address:

Article Synopsis
  • The study examined the agreement between self-reported PTSD symptom severity (PCL-5) and clinician-rated severity (CAPS-5) among US Veterans and service members, aiming to predict treatment improvement post-Intensive Outpatient Treatment Program (IOP).
  • Participants were categorized into three groups based on their reporting consistency: Congruent reporters, Limited Over-reporters, and Extensive Over-reporters.
  • Findings revealed that Extensive Over-reporters experienced the greatest reduction in PTSD symptoms after treatment compared to the Congruent and Limited Over-reporters, suggesting that understanding these reporting differences can enhance personalized PTSD treatment strategies.
View Article and Find Full Text PDF

Psychedelic risks and benefits: A cross-sectional survey study.

J Psychopharmacol

November 2024

Department of Psychiatry and Behavioral Sciences, Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Background: As classic psychedelics' therapeutic potential is studied and their popularity continues to rise, it is important to establish their relative risks and benefits. Previous surveys have tended to use convenience sampling on social media, select participants who have had either extremely positive or negative effects, and have not compared the risk/benefit profile of psychedelics to other substances.

Aims: To address these limitations, we gathered samples from an opt-in panel service using quota-based sampling to approximate demographics representing US Census data, did not pre-specify positive or negative experiences, and compared experiences with psychedelics to those with cannabis.

View Article and Find Full Text PDF
Article Synopsis
  • Psychedelic-assisted therapy (PAT) with substances like psilocybin and MDMA shows potential for treating depression and PTSD, with possible approval as medicines within the next decade.
  • A study involving 879 U.S. healthcare professionals found most respondents had strong belief in the therapeutic benefits of these substances, but exhibited low knowledge about their risks and uses.
  • Factors such as prior psychedelic use, greater self-rated knowledge, younger age, and specific professional roles influenced openness to using these therapies, highlighting the need for more training and education on the topic.
View Article and Find Full Text PDF

Dysfunctional attitudes - a cornerstone to cognitive psychotherapy - vary with both psychological and pharmacological interventions. Post-acute changes in these cognitions appear to covary with the acute reactions to psychedelics that often precede improved outcomes. An examination of post-acute changes in dysfunctional attitudes could support targeting them in psychedelic-assisted therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!